A new vaccination programme aimed at protecting new born babies and older adults against the Respiratory Syncytial Virus (RSV) and its complications has been approved in Northern Ireland.

But which ones should you get? This year marks the second season for the new respiratory syncytial virus vaccine (RSV) for grown-ups. While not everyone needs it, the evidence so far suggests that ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

Real-World Study Confirms RSV Vaccine's Protective Power for Seniors By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 18, 2024 (HealthDay News) -- A global real-world study of the vaccine for ...

What is this silent virus that endangers Filipino Seniors with comorbidities? Respiratory Syncytial Virus (RSV) is not just another cold or flu—it is potentially life- threatening for seniors ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat By Dennis Thompson HealthDay Reporter WEDNESDAY, Oct. 16, 2024 (HealthDay News) -- Public concerns about contracting RSV ...

New vaccines to prevent RSV help address the burden of RSV in older adults and help prevent infection in infants through the vaccination of pregnant individuals. RSV can affect the lower ...

Beyfortus is the first long-acting antibody approved in Canada for the prevention of RSV lower respiratory tract disease in newborns and infants through their first RSV season. Sanofi noted that ...

Clover Biopharmaceuticals announced promising results from its Phase I trial of the RSV vaccine candidate SCB-1019, demonstrating comparable immunogenicity to GSK’s AREXVY while showing ...